C.R. Jackson
Biotech, healthcare, value, research analyst

Near A 52-Week Low, Is OncoGenex Pharmaceuticals A Buy?

Approximately 90% of cancer patients with metastatic breast, prostate, lung or colon cancers develop resistance to chemotherapy. Despite scientific advances, cancer treatment failure due to treatment resistance is a major problem in oncology.

OncoGenex Pharmaceuticals Inc. (NASDAQ:OGXI) has focused its efforts on the development of therapeutics that target important mechanisms of cancer treatment resistance with the potential to improve treatment outcomes for patients with a variety of cancers.

The company was established in May 2000 as a spin-out from the Prostate Centre at Vancouver General Hospital and the University of British Columbia. It was co-founded by urologist Martin Gleave, MD, and Scott Cormack, OncoGenex' President and CEO, initially to develop and commercialize custirsen (OGX-011), which was...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
FREESA PRO MEMBERS
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details